Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study. The patients were categorized into two groups based on their age. The different age groups were further divided into the recommended RTX group and the low-dose and long-course RTX group. Compare the outcomes and adverse events of patients between different groups after 9-month follow-up.
Results: There was no significant difference in the complete remission rate and composite remission rate in patients with IMN in different age who received different RTX regimens. As expected, the risk of adverse events was higher in the recommended-dose RTX group compared with the low-dose and long-course RTX group in patients with IMN aged ≥60 years (66.7% vs. 19%, = .006), and the main adverse event was infection ( = .019). Moreover, we found that different regimens were independent risk factor for infection in patients with IMN aged ≥60 years. Furtherly, ROC curve analysis suggest that in the first month after RTX used, compared with the percentage of CD19 B lymphocytes, the percentage of eosinophilic granulocytes was more sensitive in predicting the risk of infection in elderly IMN patients (AUC = 0.329 vs. AUC = 0.555).
Conclusions: The low-dose and long-course RTX regimen should be recommended for elderly patients with IMN, and the percentage of eosinophilic granulocytes is a better risk predictor of infections after RTX used in elderly patients with IMN.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/0886022X.2025.2555688 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of rituximab in patients with PLA2R-associated membranous nephropathy of different age: a single-center retrospective cohort study.
Ren Fail
December 2025
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Background: Rituximab (RTX) has become the first-line therapy for idiopathic membranous nephropathy (IMN). The safety of low-dose and long-course RTX regimen in elderly patients with IMN remains unknown.
Methods: Sixty-nine IMN patients with anti-M-phospholipase A2 receptor (PLA2R) antibodies-positive were recruited for this study.
Comparison between anterolateral standard and percutaneous antero-acromial approach in humeral intramedullary nailing (IMN). A radiological, functional, and ultrasound rotator cuff evaluation prospective study.
Musculoskelet Surg
September 2025
Orthopaedic and Traumatology Department, ASST Sette Laghi-Circolo Hospital and Macchi Foundation in Varese University Center, Viale Luigi Borri, 57, 21100, Varese, Italy.
Purpose: The aim of this study was to evaluate the radiological-functional outcomes and rotator cuff (RC) status following humeral intramedullary nailing (IMN), comparing the anterolateral standard approach (group 1) and the percutaneous antero-acromial approach (group 2).
Methods: This observational prospective monocentric study was conducted from August 2021 to March 2023. Inclusion criteria included: two-parts proximal (surgical neck) and diaphyseal Humeral fractures treated with IMN; 12-month follow-up; age between 18 and 85 years; good performance status (excluding neurologic deficits or mental disorders).
Detecting amyloid and tau pathology in Parkinson's disease, 4R-tauopathies and control subjects with plasma pTau217.
Front Neurol
August 2025
Parkinson and Movement Disorders Unit, Study Center for Neurodegeneration (CESNE), Department of Neuroscience, University of Padova, Padua, Italy.
Introduction: Plasma phospho-tau 217 (pTau217) is a biomarker for Alzheimer's disease (AD) pathology, reflecting amyloid (Aβ) and tau burden, but its role in Parkinson disease (PD) and 4-repeat(4R)-tauopathies remains incompletely understood. We measured plasma pTau217 across the cognitive spectrum of Lewy body diseases (PD, Dementia with Lewy bodies [DLB]) and in 4R-tauopathies, comparing these groups to cognitively unimpaired (CU) and mild cognitive impairment (MCI) individuals.
Methods: Participants included 18 cognitively normal PD (PD-NC), 32 PD with MCI, and 7 PD with dementia (PDD), alongside 4 DLB patients, grouped as PDD/DLB.
Proximal humerus fractures: national treatment trends with associated 30- and 90-day readmission rates.
Injury
August 2025
Hackensack University Medical Center, Department of Orthopaedic Surgery, Hackensack, NJ, USA.
Background: The incidence of proximal humerus fractures is rising, with increasing use of reverse total shoulder arthroplasty (rTSA). This study analyzed treatment trends, readmission rates, and causes of readmission.
Methods: The Nationwide Readmissions Database (NRD) was queried for admissions with a primary diagnosis of proximal humerus fracture in the U.
Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker Study.
Ann Neurol
August 2025
Clinical Investigation Center CIC1436, Department of Clinical Pharmacology and Neurosciences, Parkinson Expert Centre and NeuroToul Center of Excellence in Neurodegeneration (COEN) of Toulouse; INSERM, University of Toulouse, CHU of Toulouse, Toulouse, France.
Objective: The objective of this study was to characterize changes in candidate biomarkers in early multiple system atrophy (MSA) and identify baseline predictors of faster progression.
Methods: This 1-year, multicenter, prospective study assessed clinical, neuroimaging (3T-magnetic resonance imaging [MRI], dopamine transporter single-photon emission computed tomography [DaT-SPECT]), and neurofilament light chain (NfL) changes in patients with early MSA (< 5 years from symptom onset) and healthy controls (HCs). Clinical and biomarker changes from baseline to 6 months (M6) and 12 months (M12) were analyzed.